evidencebas
guidelin
produc
systemat
literatur
review
rang
issu
involv
prevent
diagnosi
treatment
hospitalacquir
pneumonia
hap
prevent
structur
section
address
gener
issu
equip
patient
procedur
environ
wherea
treatment
structur
address
use
antimicrobi
prevent
treatment
adjunct
therapi
applic
clinic
protocol
section
deal
diagnosi
present
clinic
radiolog
microbiolog
diagnosi
hap
recommend
also
made
upon
role
invas
sampl
quantit
microbiolog
respiratori
secret
direct
antibiot
therapi
hapventilatorassoci
pneumonia
hospitalacquir
pneumonia
hap
respiratori
infect
develop
h
hospit
admiss
hap
affect
inpati
common
healthcareassoci
infect
hcai
contribut
death
estim
increas
hospit
stay
day
proport
patient
hap
associ
mechan
ventil
case
term
ventilatorassoci
pneumonia
vap
patient
vap
mortal
rate
increas
infect
caus
multidrugresist
pathogen
vap
account
intens
care
unit
icu
infect
risk
highest
earli
icu
stay
estim
day
first
day
ventil
follow
day
day
ventil
thereaft
day
featur
high
incid
signific
morbid
mortal
consequ
driven
consider
recent
interest
creation
hap
guidelin
prevent
hap
therefor
desir
also
essenti
provid
costeffect
healthcar
depart
health
dh
save
live
initi
seven
highimpact
intervent
part
programm
reduc
hcai
one
relat
care
ventil
patient
although
guidelin
hap
uk
previous
publish
total
intern
hap
guidelin
releas
last
year
one
use
systemat
review
literatur
approach
cover
prevent
diagnosi
treatement
american
thorac
societi
guidelin
howev
use
semiqualit
approach
assess
weigh
fulli
strength
qualiti
evid
half
avail
guidelin
base
expert
opinion
cover
one
two
three
work
diagnosi
divid
three
section
cover
main
diagnost
approach
hap
clinic
assess
radiolog
investig
microbiolog
investig
similarli
treatment
divid
five
section
includ
differ
aspect
patient
care
cover
use
antimicrobi
prevent
treatment
role
invas
sampl
quantit
microbiolog
respiratori
secret
direct
antibiot
therapi
use
adjunct
therapi
applic
clinic
protocol
limit
number
studi
address
issu
includ
four
cohort
studi
one
case
control
studi
data
two
cohort
studi
show
educ
programm
effect
reduc
incid
vap
respect
cohort
studi
also
show
introduc
protocol
educ
effect
reduc
vap
one
cohort
studi
case
control
studi
demonstr
part
broad
intervent
program
educ
success
control
stafftostaff
stafftopati
outbreak
primari
respiratori
pathogen
eg
pertussi
respiratori
syncyti
viru
cohort
studi
show
higher
proport
care
provid
qualifi
regist
nurs
staff
lower
incid
hap
studi
therefor
consist
provid
evid
staff
educ
programm
part
overal
infect
control
programm
reduc
incid
vap
recommend
hospit
educ
programm
part
overal
infect
control
strategi
form
part
risk
reduct
measur
hap
recommend
grade
b
grade
recommend
least
one
metaanalysi
systemat
review
rct
rate
directli
applic
target
popul
systemat
review
rct
bodi
evid
consist
princip
studi
rate
directli
applic
target
popul
demonstr
overal
consist
result
b
bodi
evid
includ
studi
rate
directli
applic
target
popul
demonstr
overal
consist
result
extrapol
evid
studi
rate
c
bodi
evid
includ
studi
rate
directli
applic
target
popul
demonstr
overal
consist
result
extrapol
evid
studi
rate
evid
level
extrapol
evid
studi
level
good
practic
point
gpp
recommend
best
practic
base
clinic
experi
hap
work
parti
bsac
rct
random
control
trial
see
ref
definit
evid
assess
appropri
level
experienc
nurs
staff
involv
patient
care
prevent
hap
educ
staff
measur
taken
prevent
hap
form
part
induct
continu
profession
develop
recommend
grade
gpp
publish
guidelin
relat
specif
prevent
vap
rather
hap
two
random
control
trial
rct
show
care
protocol
icu
decreas
incid
vap
particularli
trauma
patient
two
rct
specif
use
wean
protocol
ventil
patient
icu
found
use
protocol
nurs
respiratori
therapist
result
reduc
durat
mechan
ventil
improv
clinic
outcom
reduc
cost
also
use
protocol
reduc
sedat
report
effect
shorten
durat
ventil
icu
stay
although
paper
identifi
provid
good
evid
clinic
guidelin
reduc
incid
vap
direct
evid
guidelin
affect
incid
hap
outsid
icu
recommend
made
respect
valu
clinic
guidelin
implement
scenario
recommend
care
protocol
guidelin
wean
sedat
develop
activ
follow
critic
care
set
reduc
incid
vap
recommend
grade
order
reduc
incid
hap
adher
clinic
guidelin
monitor
ensur
complianc
recommend
grade
gpp
studi
examin
benefit
routin
surveil
hap
organ
patient
environ
prevent
hap
recommend
made
topic
futur
research
recommend
order
assess
whether
take
routin
screen
sampl
patient
help
reduc
incid
hap
assist
target
treatment
earli
recognit
organ
caus
hap
work
also
need
assess
whether
routin
screen
environ
organ
caus
hap
reduc
incid
hap
due
multiresist
gramneg
bacteria
eg
pseudomona
aeruginosa
acinetobact
spp
recommend
limit
target
surveil
organ
caus
pneumonia
icu
patient
carri
identifi
crossinfect
outbreak
infect
control
problem
eg
singl
case
hospitalacquir
legionella
infect
type
surveil
also
help
provid
feedback
assist
clinician
empir
antibiot
select
incid
suscept
organ
caus
vap
recommend
grade
gpp
immun
prevent
hap
immun
relev
prevent
hap
includ
particularli
influenza
pneumococc
vaccin
publish
paper
cover
influenza
includ
influenza
pneumonia
elderli
healthcar
worker
mainli
relat
outbreak
nurs
home
metaanalysi
review
area
includ
observ
studi
hap
elderli
also
cohort
studi
three
rct
exist
uk
guidanc
alreadi
highlight
import
immun
influenza
pneumococc
diseas
highrisk
adult
paediatr
patient
immun
healthcar
worker
involv
atrisk
patient
also
recommend
howev
direct
evid
influenza
immun
healthcar
worker
patient
directli
reduc
incid
hap
although
one
studi
found
evid
suggest
influenza
immun
prevent
pneumonia
elderli
patient
studi
report
failur
immun
healthcar
worker
influenza
associ
increas
mortal
influenza
like
ill
elderli
patient
also
direct
evid
pneumococc
immun
healthcar
worker
patient
reduc
incid
hap
recommend
use
influenza
immun
healthcar
worker
patient
pneumococc
immun
elderli
atrisk
group
encourag
line
recommend
joint
committe
vaccin
immun
influenza
immun
activ
encourag
atrisk
patient
healthcar
worker
recommend
grade
gpp
number
studi
assess
effect
hand
hygien
stafftopati
stafftoequip
transfer
bacteria
good
evid
invers
relationship
exist
high
standard
hand
hygien
incid
hcai
good
evid
direct
relationship
prevent
hap
hand
hygien
effect
reduc
hcai
epic
project
evidencebas
guidelin
prevent
hcai
recommend
implement
hand
hygien
polici
recommend
hand
hygien
guidelin
avail
part
evidencebas
process
prevent
hcai
follow
hand
hygien
practic
incorpor
clinic
guidelin
prevent
hap
perform
audit
carri
demonstr
maintain
high
level
practic
recommend
grade
gpp
view
reduc
incid
hap
staff
hand
hygien
form
part
routin
care
hand
decontamin
immedi
everi
episod
direct
patient
contact
activ
contact
potenti
result
hand
becom
contamin
hand
decontamin
glove
remov
perform
recommend
grade
gpp
absenc
evid
address
issu
studi
avail
relat
hcai
directli
hap
data
show
appropri
use
person
protect
equip
ppe
prevent
spread
microorgan
hcai
might
potenti
reduc
incid
hap
essenti
choic
ppe
appropri
risk
infect
eg
simpl
surgic
mask
inadequ
protect
tuberculosi
respiratori
virus
appropri
equip
need
readili
avail
necessari
train
given
use
nation
health
safeti
work
requir
ppe
regul
control
substanc
hazard
health
regul
follow
recommend
role
ppe
prevent
hap
involv
local
risk
assess
refer
nation
health
safeti
work
requir
eg
ppe
regul
local
infect
control
advic
recommend
grade
recommend
high
standard
hygien
includ
hand
hygien
ppe
protect
healthcar
worker
patient
hcai
microorgan
includ
influenza
viral
respiratori
pathogen
recommend
grade
gpp
glove
put
immedi
episod
patient
contact
treatment
remov
soon
activ
complet
chang
care
differ
patient
differ
caretreat
activ
patient
recommend
grade
gpp
care
need
taken
use
ppe
prevent
spread
infect
patient
eg
glove
contamin
hand
remov
correctli
henc
import
hand
decontamin
glove
remov
recommend
grade
gpp
person
respiratori
protect
requir
certain
respiratori
infect
eg
multidrugresist
tuberculosi
human
coronaviru
etc
patient
sever
immunocompromis
expos
infect
eg
high
effici
particul
air
hepa
filter
environ
instanc
special
respiratori
protect
equip
worn
recommend
grade
gpp
nation
guidelin
follow
regard
protect
staff
highli
communic
infect
eg
human
coronaviru
recommend
grade
gpp
isol
patient
multidrugresist
infect
includ
pneumonia
perform
alongsid
use
ppe
prevent
spread
infect
recommend
grade
gpp
infect
control
issu
relat
use
equipmentbest
method
steril
disinfect
equip
mainten
instrument
respect
hap
risk
reduct
absenc
evid
best
sterilizationdisinfectionmainten
procedur
mechan
ventil
reus
singleus
devic
affect
safeti
perform
effect
expos
patient
staff
unnecessari
risk
also
carri
legal
implic
anyon
reprocess
reus
devic
intend
manufactur
use
singl
occas
bear
full
respons
item
safeti
effect
includ
organ
equip
transfer
recommend
line
medic
devic
agenc
guidanc
singleus
medic
devic
item
design
singleus
must
reus
circumst
recommend
grade
gpp
equip
steril
disinfect
maintain
accord
manufactur
instruct
recommend
grade
gpp
systemat
review
includ
four
rct
seven
observ
studi
found
chang
ventil
circuit
less
frequent
everi
h
reduc
risk
vap
anoth
systemat
review
assess
three
rct
one
consid
higher
qualiti
trial
two
review
conclud
frequenc
ventil
circuit
chang
influenc
incid
vap
less
frequent
chang
ventil
circuit
associ
harm
frequent
chang
associ
increas
cost
rct
found
differ
rate
vap
patient
ventil
circuit
contain
heat
moistur
exchang
hme
h
circuit
chang
compar
plan
chang
studi
conduct
ventil
patient
circuit
chang
sign
visibl
contamin
damag
research
regard
safeti
infect
control
criteria
requir
determin
maximum
length
time
ventil
tube
chang
provid
otherwis
chang
becom
soil
damag
recommend
ventil
circuit
need
chang
day
recommend
grade
new
ventil
circuit
tube
provid
patient
recommend
grade
b
order
prevent
contamin
healthcar
worker
facial
protect
use
alongsid
ppe
close
breath
circuit
disconnect
especi
import
deal
patient
highli
communic
infect
eg
human
coronaviru
recommend
grade
gpp
prevent
vap
breath
circuit
condens
manag
drain
toward
patient
period
drain
discard
recommend
grade
gpp
two
metaanalys
systemat
review
compar
use
heat
humidifi
hh
hme
one
metaanalysi
cover
eight
rct
cite
paper
examin
use
differ
humidifi
type
effect
incid
vap
metaanalysi
conclud
patient
ventil
day
use
hme
associ
statist
signific
reduct
incid
vap
compar
hh
wherea
concern
express
earlier
systemat
review
et
tube
obstruct
associ
hme
use
confirm
recent
studi
evalu
newer
hme
two
rct
shown
reduc
cost
associ
use
hme
compar
hh
provid
contraind
use
eg
patient
risk
airway
obstruct
recommend
hme
rather
hh
use
hme
effect
reduc
incid
vap
recommend
grade
hme
use
type
chosen
one
adequ
moistur
output
minim
risk
airway
three
rct
address
issu
two
latter
specif
evalu
effect
vap
reduc
frequenc
chang
humidifi
one
studi
look
efficaci
safeti
studi
three
differ
type
hme
report
hme
perform
equal
brand
abl
use
h
without
chang
also
report
chang
hme
day
diminish
effici
equip
increas
incid
vap
studi
evid
frequent
chang
hh
hme
manufactur
recommend
reduc
risk
hap
recommend
hh
hme
use
except
high
minut
volum
chang
routin
manufactur
guidanc
follow
recommend
grade
technic
perform
hme
h
monitor
especi
patient
chronic
obstruct
pulmonari
diseas
copd
evid
suspicion
contamin
humidifi
chang
recommend
grade
gpp
nebul
use
icu
ward
depart
deliv
bronchodil
drug
three
diagnost
studi
report
nebul
becom
contamin
act
sourc
respiratori
tract
infect
recommend
nebul
singl
patient
use
need
disinfect
clean
steril
water
use
recommend
grade
nebul
use
part
ventil
circuit
singl
use
nation
guidelin
follow
regard
use
clean
nebul
recommend
grade
gpp
report
literatur
provid
evid
support
use
filter
protect
circuit
system
bacteri
contamin
evid
establish
use
filter
specif
protect
hap
recommend
appropri
filter
use
protect
mechan
ventil
circuit
bacteri
contamin
recommend
grade
c
nation
guidelin
follow
regard
use
expiratori
filter
patient
suffer
highli
communic
infect
eg
human
coronaviru
requir
mechan
ventil
recommend
grade
gpp
suction
patient
intens
care
essenti
prevent
pool
respiratori
secret
systemat
review
three
studi
examin
effect
daili
chang
inlin
suction
equip
found
compar
less
frequent
chang
effect
incid
vap
wherea
therefor
evid
chang
close
suction
equip
daili
reduc
risk
vap
maximum
durat
close
suction
cathet
use
safeti
infect
control
consider
known
recommend
daili
chang
suction
equip
requir
recommend
grade
suction
equip
may
chang
weekli
unless
becom
contamin
damag
case
chang
immedi
recommend
grade
gpp
four
studi
use
bagvalv
mask
ventil
manual
ventilationrebreath
bag
report
resuscit
equip
act
sourc
hap
becom
bacteri
contamin
recommend
order
minim
risk
hap
multius
bagvalv
mask
ventil
manual
ventil
rebreath
bag
decontamin
accord
manufactur
guidelin
patient
use
recommend
grade
c
reusabl
resuscit
equip
appropri
decontamin
accord
manufactur
recommend
use
possibl
singl
patient
use
equip
eg
ambu
bag
employ
recommend
grade
gpp
diagnost
studi
suggest
basic
hygien
manag
anaesthet
equip
adequ
prevent
crossinfect
studi
requir
establish
best
steril
disinfect
mainten
method
reduc
risk
hap
anaesthet
machin
breath
system
recommend
reduc
risk
hap
basic
hygien
measur
adopt
anaesthet
equip
recommend
grade
provid
filter
place
protect
equip
anaesthet
equip
decontamin
accord
manufactur
instruct
recommend
grade
gpp
chang
hme
anaesthet
machin
valv
patient
weekli
circuit
chang
adequ
prevent
infect
anaesthet
machin
anaesthet
equip
use
known
infect
patient
tube
filter
chang
next
patient
use
recommend
grade
gpp
report
use
spiromet
associ
hap
caus
acinetobact
spp
one
studi
report
mouthpiec
spirometri
tube
becom
contamin
bacteria
use
recommend
prevent
acquisit
microorgan
caus
hap
share
patient
recommend
spirometri
mouthpiec
singl
use
recommend
grade
c
respiratori
equip
contamin
respiratori
secret
possibl
view
potenti
infect
risk
hap
therefor
precaut
taken
reduc
risk
recommend
conclud
type
suction
system
effect
incid
vap
two
rct
confirm
find
howev
one
rct
report
time
greater
risk
vap
patient
receiv
open
versu
close
suction
studi
therefor
show
close
oppos
open
suction
respiratori
tract
secret
affect
risk
vap
evid
close
suction
increas
risk
vap
recommend
made
use
close
suction
reduc
risk
hap
patient
recommend
close
open
suction
system
use
without
affect
risk
vap
recommend
grade
b
safeti
perspect
close
suction
respiratori
tract
secret
valu
reduc
aerosol
respiratori
tract
secret
protect
healthcar
worker
number
disconnect
suction
equip
minim
reduc
risk
exposur
staff
potenti
infect
secret
recommend
grade
gpp
use
noninvas
posit
pressur
ventil
niv
involv
provid
respiratori
support
patient
without
need
intub
evid
select
patient
niv
reduc
risk
hap
cochran
systemat
review
includ
five
rct
found
patient
copd
niv
reduc
risk
hap
although
indic
procedur
rel
narrow
number
patient
appli
larg
recommend
reduc
risk
hap
niv
rather
mechan
ventil
use
appropri
patient
recommend
grade
one
rct
specif
address
issu
oral
versu
nasotrach
intub
regard
develop
vap
wherea
four
rct
also
assess
develop
maxillari
sinus
demonstr
associ
nasotrach
intub
maxillari
sinus
anoth
studi
show
reintub
associ
increas
incid
vap
recommend
possibl
oral
et
intub
use
prefer
nasotrach
intub
reintub
avoid
possibl
recommend
grade
c
enter
feed
use
prevent
develop
catabol
state
patient
requir
longterm
ventil
cohort
studi
ventil
patient
show
relationship
enter
feed
aspir
limit
evid
support
also
absenc
evid
incid
hap
ventil
patient
reduc
take
measur
reduc
aspir
associ
enter
feed
view
find
recommend
made
use
enter
feed
prevent
hap
recommend
ventil
patient
rate
volum
enter
feed
adjust
avoid
gastric
distens
reduc
risk
aspir
recommend
grade
gpp
number
method
provid
enter
feed
assess
systemat
review
four
rct
evalu
differ
method
enter
feed
includ
intermitt
feed
use
metoclopramid
acidif
feed
review
differ
incid
vap
mortal
found
strategi
metaanalysi
seven
rct
look
specif
postpylor
feed
report
compar
gastric
feed
associ
signific
reduct
vap
suggest
studi
warrant
second
metaanalysi
includ
nine
rct
compar
gastric
versu
postpylor
feed
found
signific
differ
incid
vap
group
research
requir
studi
effect
differ
mode
feed
incid
hap
recommend
clear
evid
intermitt
feed
small
intestin
feed
use
metoclopramid
acidif
feed
prevent
vap
decis
method
enter
feed
use
critic
ill
patient
made
local
unit
individu
patient
basi
recommend
grade
enter
feed
use
method
deliveri
optim
patient
recommend
grade
gpp
relationship
aspir
gastric
content
pneumoniapneumon
well
known
although
absenc
evid
prevent
aspir
associ
et
intub
reduc
incid
hap
cohort
studi
report
wit
aspir
associ
increas
risk
vap
metaanalysi
found
establish
subglott
drainag
effect
prevent
earlyonset
vap
patient
expect
remain
ventil
h
recommend
prevent
vap
measur
taken
reduc
risk
aspir
includ
subglott
drainag
posit
recommend
grade
b
attent
need
paid
et
cuff
pressur
avoid
aspir
prevent
tracheal
damag
cm
water
recommend
grade
gpp
clear
evid
reduct
gastric
acid
variou
method
includ
antacid
antagonist
use
stress
ulcer
prophylaxi
icu
patient
ventil
increas
risk
vap
howev
literatur
consist
regard
use
sucralf
context
systemat
review
consid
seven
metaanalys
found
evid
four
sucralf
compar
antagonist
significantli
reduc
incid
vap
three
metaanalys
show
statist
signific
reduct
vap
use
sucralf
show
trend
effect
larg
rct
found
mechan
ventil
patient
sucralf
therapi
associ
statist
significantli
increas
risk
clinic
import
gastrointestin
bleed
compar
antagonist
therefor
evid
use
sucralf
associ
reduc
risk
vap
compar
use
agent
rais
gastric
alkalin
ventil
patient
sucralf
therapi
associ
increas
risk
clinic
import
gastrointestin
bleed
compar
ranitidin
recommend
whenev
clinic
appropri
stress
ulcer
prophylaxi
avoid
order
help
preserv
gastric
function
recommend
grade
recommend
stress
ulcer
prophylaxi
indic
sucralf
prefer
order
reduc
risk
vap
sucralf
use
patient
low
moder
risk
gastrointestin
bleed
recommend
grade
absenc
evid
instruct
patient
cough
take
deep
breath
reduc
incid
hap
two
cohort
studi
rct
specif
look
hap
consid
pulmonari
complic
gener
anoth
studi
found
effect
regimen
prophylaxi
pulmonari
complic
lowrisk
patient
abdomin
surgeri
deep
breath
recommend
cough
earli
mobil
postop
recoveri
period
encourag
patient
order
reduc
risk
pulmonari
complic
recommend
grade
gpp
found
data
role
physiotherapist
respiratori
therapist
reduc
incid
hap
gener
howev
one
studi
show
benefit
chest
physiotherapi
prevent
vap
wherea
rct
demonstr
physiotherapi
incent
spirometri
reduc
respiratori
complic
highrisk
surgic
patient
systemat
review
assess
role
respiratori
therapist
report
five
rct
show
respiratori
therapist
effect
implement
respiratori
care
protocol
wean
patient
mechan
ventil
appropri
alloc
respiratori
care
adult
nonicu
patient
relat
either
featur
hap
prevent
therefor
evid
respiratori
therapist
follow
wean
protocol
reduc
durat
mechan
ventil
icu
stay
improv
outcom
also
physiotherapi
incent
spirometri
highrisk
abdomin
surgeri
patient
reduc
respiratori
complic
includ
pneumonia
research
requir
establish
role
physiotherapi
prevent
manag
hap
recommend
physiotherapist
respiratori
therapist
role
prevent
respiratori
complic
postop
ventil
patient
recommend
grade
physiotherapist
respiratori
therapist
holist
role
preand
postop
care
patient
especi
highrisk
patient
risk
assess
indic
may
valu
recommend
grade
gpp
evid
use
incent
spirometri
postop
highrisk
surgic
patient
may
benefici
although
poor
one
rct
absenc
evid
incent
spirometri
impact
reduc
risk
hap
lowrisk
surgic
patient
abdomin
surgeri
research
requir
assess
effect
incent
spirometri
patient
requir
surgeri
recommend
incent
spirometri
role
play
prevent
hap
lowrisk
asa
grade
surgic
patient
includ
patient
preexist
pulmonari
complic
use
highrisk
patient
prevent
respiratori
complic
recommend
grade
sever
studi
look
use
semirecumb
prone
supin
posit
relat
risk
hap
rct
found
use
semirecumb
posit
may
prevent
vap
also
report
supin
bodi
posit
enter
feed
independ
risk
factor
develop
nosocomi
pneumonia
np
howev
earlier
studi
smaller
number
patient
conclud
semirecumb
posit
prevent
vap
anoth
rct
look
effect
prone
posit
patient
acut
respiratori
failur
found
gener
benefit
use
prone
posit
concern
safeti
howev
cohort
studi
show
patient
nurs
supin
head
posit
first
h
ventil
increas
risk
vap
studi
report
signific
increas
vap
patient
transport
icu
intervent
like
relat
posit
recommend
posit
strategi
adopt
prevent
vap
patient
requir
supin
provid
contraind
consider
given
use
semirecumb
posit
order
prevent
aspir
patient
kept
semirecumb
posit
enter
feed
gpp
limit
amount
evid
use
kinet
bed
prevent
hap
metaanalysi
includ
six
studi
systemat
review
cover
eight
rct
review
use
kinet
oscil
bed
conclus
although
may
impact
reduc
complic
associ
intens
care
inconclus
whether
affect
develop
hap
present
recommend
use
kinet
therapi
prevent
hap
made
evid
research
requir
assess
valu
kinet
therapi
prevent
hap
differ
patient
popul
especi
icu
use
transfus
particularli
studi
postop
patient
receiv
intens
care
one
studi
demonstr
transfus
u
red
cell
concentr
associ
increas
risk
hap
cardiac
surgeri
patient
wherea
anoth
cohort
studi
show
use
store
red
blood
cell
increas
risk
hap
contradistinct
studi
report
restrict
transfus
polici
icu
patient
least
effect
liber
polici
regard
effect
mortal
multiorgan
failur
final
cohort
studi
report
leucocytedeplet
blood
better
buffycoat
reduc
blood
prevent
pneumonia
patient
undergo
colorect
surgeri
therefor
evid
use
red
cell
transfus
increas
risk
hap
evid
avail
particularli
applic
cardiac
colorect
surgeri
research
need
carri
establish
effect
red
cell
transfus
develop
hap
patient
group
recommend
prevent
hap
red
cell
transfus
avoid
possibl
use
fresh
red
cell
recommend
grade
c
number
studi
demonstr
associ
build
work
environment
contamin
aspergillu
pulmonari
aspergillosi
good
evid
method
reduc
dust
level
result
lower
level
fungal
spore
environ
reduc
incid
pulmonari
aspergillosi
build
work
howev
studi
systemat
look
risk
relat
type
build
work
construct
versu
demolit
rel
contribut
variou
strategi
reduc
risk
ie
dust
reduct
ii
air
handl
iii
environment
air
monitor
iv
antifung
prophylaxi
financi
impact
measur
simpl
dust
reduct
use
introduc
widespread
environment
control
expens
eg
hepa
filtrat
moreov
absenc
evid
routin
monitor
spore
count
build
work
use
although
recommend
author
especi
highrisk
area
studi
shown
although
protect
environ
hepa
filtrat
reduc
incid
invas
aspergillosi
ia
haemopoiet
stem
cell
transplant
hsct
patient
may
prevent
ia
build
work
recommend
build
work
consider
given
address
risk
pulmonari
aspergillosi
must
includ
identifi
highrisk
patient
ie
acut
leukaemia
hsct
patient
patient
receiv
chemotherapi
result
sever
prolong
neutropenia
immunosuppress
patient
includ
longterm
corticosteroid
immunosuppress
therapi
method
reduc
patient
exposur
aspergillu
eg
use
floor
ceil
barrier
seal
window
use
hepa
filtrat
highrisk
unit
eg
hsct
unit
critic
care
dust
reduct
clinic
area
includ
clean
damp
dust
use
hepafilt
vacuum
cleaner
routin
monitor
air
fungal
spore
build
work
outsid
highrisk
area
recommend
recommend
grade
build
work
environment
monitor
fungal
spore
critic
area
hous
atrisk
patient
use
monitor
effect
control
measur
outbreak
situat
environment
air
monitor
may
use
identifi
sourc
infect
recommend
grade
gpp
ventil
system
especi
hepa
filter
may
becom
contamin
build
work
build
work
filter
regularli
inspect
replac
necessari
recommend
grade
gpp
sever
outbreak
aspergillu
infect
associ
build
work
rais
issu
regard
addit
patientfocus
method
use
prevent
infect
includ
use
antifung
agent
good
evid
widespread
use
antifung
treatment
prophylaxi
construct
work
small
cohort
studi
report
antifung
prophylaxi
immunocompromis
patient
construct
work
reduc
ia
good
evid
protect
effect
ia
antifung
prophylaxi
neutropen
patient
gener
specif
support
use
itraconazol
situat
clear
evidencebas
indic
use
antifung
prophylaxi
recommend
high
institut
rate
ia
build
work
underway
risk
assess
undertaken
patient
immunosuppress
especi
neutropen
neutrophil
count
l
week
l
week
visit
hospit
regularli
stay
inpati
hepafilt
environ
consid
antifung
prophylaxi
recommend
grade
use
antifung
prevent
ia
immunosuppress
build
work
base
robust
risk
assess
individu
patient
recommend
grade
gpp
cost
use
antifung
prophylaxi
therefor
consid
build
project
cost
drug
monitor
larg
hospit
project
eg
involv
demolit
reconstruct
addit
cost
may
need
cover
sever
month
recommend
grade
gpp
good
evid
base
show
relationship
legionella
contamin
hospit
water
hospitalacquir
ha
legionella
pneumonia
also
good
evid
control
risk
legionella
hospit
water
suppli
reduc
risk
ha
legionella
pneumonia
larg
bodi
evid
regard
method
control
legionella
hospit
water
suppli
consist
cohort
casecontrol
studi
health
safeti
execut
hse
also
issu
comprehens
guidanc
control
legionella
hospit
recent
revalu
method
avail
control
legionella
water
system
includ
heat
ii
biocid
eg
chlorin
chlorin
dioxid
iii
ioniz
eg
copper
silver
iv
ultraviolet
light
ozon
studi
compar
differ
method
result
across
method
consist
demonstr
process
effect
reduc
legionella
load
hospit
water
although
effect
may
temporari
howev
possibl
make
full
comparison
differ
method
hospit
alreadi
adher
dh
advic
control
legionella
hospit
addit
financi
consequ
research
requir
confirm
relationship
environment
legionella
ha
legionnair
diseas
includ
establish
rel
import
differ
serogroup
legionella
pneumophila
legionella
spp
research
requir
differ
method
control
legionella
appropri
use
differ
healthcar
set
although
recommend
made
appropri
method
recommend
line
current
guidanc
appropri
legionella
control
hospit
water
requir
recommend
grade
b
uk
hse
guidanc
legionnair
diseasecontrol
legionella
bacteria
water
system
nation
guidanc
follow
recommend
grade
gpp
secondari
prevent
ie
prevent
case
case
hospitalacquir
infect
addit
measur
may
requir
eg
use
biocid
heat
flush
etc
recommend
grade
gpp
routin
cultur
hospit
water
legionella
recommend
appropri
highrisk
area
eg
haemopoiet
stem
cell
solid
organ
transplant
ward
infect
control
team
work
close
hospit
engin
manag
physician
ensur
awar
ha
legionnair
diseas
recommend
grade
gpp
cleanli
environ
highlight
dh
save
live
initi
essenti
prevent
hcai
small
number
cohort
studi
demonstr
environment
risk
relat
poor
clean
eg
infect
methicillinresist
staphylococcu
aureu
mrsa
clostridium
difficil
relat
directli
hap
specif
icu
small
number
studi
describ
environ
act
reservoir
organ
caus
infect
patient
though
also
relat
directli
hap
icu
studi
demonstr
take
action
remov
reservoir
effect
prevent
infect
epic
project
review
reveal
littl
research
evid
accept
qualiti
upon
base
guidanc
relat
hospit
environment
hygien
howev
note
larg
bodi
clinic
evid
deriv
case
report
outbreak
investig
show
link
poor
environment
hygien
transmiss
microorgan
caus
hcai
given
rout
transmiss
organ
caus
hap
differ
describ
avail
report
issu
relat
mainli
direct
contact
contamin
spread
applic
avail
evid
directli
relat
hap
strong
possibl
gener
avail
evid
low
volum
directli
relat
hap
icu
instanc
clean
small
volum
research
avail
consist
demonstr
environ
act
reservoir
infect
take
action
remov
reservoir
effect
prevent
infect
consist
evid
make
extrapol
issu
reason
publish
cleanli
standard
healthprovid
facil
form
part
perform
assess
review
recommend
order
reduc
risk
hcai
includ
hap
good
approv
standard
hospit
cleanli
maintain
recommend
grade
hospit
environ
must
visibl
clean
free
dust
soilag
accept
patient
visitor
staff
recommend
grade
gpp
staff
involv
hospit
hygien
activ
undergo
educ
train
relat
prevent
hcai
train
includ
link
infect
cleanli
environ
recommend
grade
gpp
diagnosi
hap
np
usual
defin
pneumonia
develop
h
admiss
hospit
incub
time
admiss
vap
usual
defin
pneumonia
develop
h
implement
et
intub
andor
mechan
ventil
present
intub
hap
divid
earlyand
lateonset
earlyonset
diseas
occur
within
day
admiss
tend
caus
antibioticsuscept
communitytyp
pathogen
wherea
late
infect
tend
caus
antibioticresist
hospit
opportunist
howev
studi
found
increas
frequenc
earlyonset
hap
caus
pathogen
commonli
associ
nosocomi
diseas
contribut
concept
healthcareassoci
pneumonia
hcap
involv
pathogen
associ
recent
prior
hospit
andor
antimicrobi
therapi
hcap
defin
pneumonia
occur
patient
admit
acut
care
hospit
day
within
day
infect
resid
nurs
home
longterm
care
facil
attend
hospit
haemodialysi
clinic
receiv
recent
intraven
antibiot
therapi
chemotherapi
wound
care
within
past
day
current
infect
rare
hapvap
due
fungal
infect
usual
although
exclus
seen
sever
immunocompromis
patient
vap
also
divid
earlyand
lateonset
earlyonset
vap
occur
first
day
mechan
ventil
pneumonia
often
caus
typic
commun
organ
lateonset
vap
develop
day
initi
mechan
ventil
commonli
caus
typic
opportunist
antibioticresist
hospit
pathogen
p
aeruginosa
mrsa
two
fundament
problem
assess
diagnost
literatur
relat
hap
first
public
deal
vap
wherea
hap
occur
nonventil
nonintub
patient
may
valid
extrapol
diagnost
criteria
vap
hap
exampl
diagnosi
vap
often
involv
invas
microbiolog
sampl
may
possibl
appropri
nonintub
patient
second
problem
univers
accept
gold
refer
standard
diagnost
criteria
hap
vap
difficult
compar
differ
diagnost
method
studi
begin
divid
patient
group
pneumonia
without
criteria
use
divis
vari
problem
thu
studi
group
patient
probabl
pneumonia
probabl
unknown
proport
wrongli
classifi
exampl
patient
thought
hap
clinic
diagnos
autopsi
vice
versa
exclud
studi
analysi
interpret
result
caution
recent
use
studi
appear
avoid
problem
analys
outcom
manag
base
differ
diagnost
techniqu
singl
group
patient
suspect
hap
assess
lung
histolog
cultur
refer
standard
diagnosi
hap
lung
biopsi
impract
associ
risk
rare
use
diagnosi
hap
recommend
purpos
nevertheless
histolog
cultur
homogen
lung
tissu
frequent
use
valid
diagnost
test
quantit
microbiolog
respiratori
specimen
experiment
baboon
model
vap
use
assess
sever
bronchopneumonia
lung
histolog
compar
quantit
microbiolog
lung
tissu
bronchoalveolar
lavag
bal
specimen
moder
sever
pneumonia
judg
histolog
associ
high
bacteri
concentr
homogen
lung
biopsi
bacteri
concentr
bal
linearli
relat
tissu
valu
led
concept
quantit
bacteriolog
bal
deep
respiratori
specimen
could
use
accur
diagnosi
hapvap
mani
subsequ
studi
pneumonia
human
patient
use
lung
histolog
quantit
microbiolog
respiratori
secret
refer
standard
assess
diagnost
method
howev
sever
studi
lung
biopsi
cultur
shown
inconsist
result
prospect
case
studi
post
mortem
lung
biopsi
perform
h
death
patient
mechan
ventil
day
histolog
pneumonia
diagnos
four
independ
pathologist
case
respect
one
pathologist
review
slide
blindli
month
later
reclassifi
two
patient
one
diagnos
one
without
pneumonia
singl
pathologist
review
slide
johanson
et
al
criteria
diagnos
pneumonia
patient
later
prospect
case
studi
quantit
microbiolog
open
lung
biopsi
ventil
patient
found
histolog
lesion
pneumonia
tissu
concentr
bacteria
unevenli
distribut
lung
parenchyma
quantit
tissu
bacteri
concentr
tend
correl
presenc
sever
histolog
lesion
could
differenti
histolog
presenc
absenc
pneumonia
similar
result
obtain
other
recommend
lung
histolog
reli
upon
goldrefer
standard
diagnosi
hap
recommend
grade
biopsi
use
refer
standard
diagnost
method
hap
histolog
criteria
standard
recommend
grade
gpp
histolog
diagnosi
hap
quantif
bacteri
lung
tissu
concentr
base
sever
specimen
differ
area
lung
recommend
grade
gpp
studi
use
histolog
parenchym
cultur
refer
standard
assess
diagnost
criteria
hap
interpret
caution
recommend
grade
gpp
clinic
diagnosi
pneumonia
hap
vap
difficult
univers
accept
clinic
criteria
systemat
review
cover
clinic
diagnosi
vap
consid
public
wherea
evid
compris
cohort
studi
consensu
opinion
clinic
diagnost
criteria
describ
consensu
opinion
statement
vap
hap
communityacquir
pneumonia
cap
howev
overlap
clinic
sign
symptom
pneumonia
form
sepsi
diagnosi
hap
often
made
clinic
criteria
alon
reserv
diagnost
sensit
clinic
suspicion
improv
take
account
presenc
fever
core
temperatur
blood
leucocytosi
leucocytesmm
leucopenia
purul
tracheal
secret
presenc
new
andor
persist
infiltr
chest
radiograph
cxr
otherwis
unexplain
howev
clinic
criteria
requir
diagnosi
specif
would
poor
european
consensu
group
believ
diagnosi
pneumonia
could
base
pulmonari
infiltr
plu
two
criteria
patient
increas
sever
pneumonia
may
associ
increas
evid
circulatori
collaps
shock
tachycardia
hypotens
elev
blood
urea
concentr
howev
sign
sepsi
specif
pneumonia
requir
diagnosi
hap
vap
compar
studi
immedi
post
mortem
histolog
patient
mechan
ventil
day
assess
five
clinic
diagnost
criteria
fever
leucocytosi
posit
sputum
cultur
worsen
cxr
chang
worsen
ga
exchang
none
individu
clinic
criteria
combin
correl
presenc
absenc
histolog
pneumonia
thu
moder
amount
evid
compar
clinic
diagnost
criteria
refer
criteria
includ
histolog
data
demonstr
consider
variat
clinic
present
hap
distinct
form
sepsi
difficult
clinic
pulmonari
infect
score
cpi
evolv
clinic
score
system
approach
diagnosi
hap
base
six
criteria
origin
fourfev
leucocytosi
posit
sputum
cultur
worsen
cxr
changesplu
oxygen
pao
fio
semiquantit
cultur
tracheal
aspir
without
gram
stain
develop
claim
increas
diagnost
sensit
prospect
case
seri
studi
deceas
patient
mechan
ventil
death
presenc
histolog
pneumonia
posit
lung
cultur
immedi
post
mortem
use
refer
test
vap
patient
cpi
superior
convent
clinic
criteria
diagnosi
vap
death
prospect
cohort
studi
investig
util
modifi
cpi
diagnosi
hap
convent
clinic
diagnosi
found
inaccur
sensit
specif
cpi
slightli
accur
sensit
specif
ad
gram
stain
result
bal
specimen
slightli
increas
accuraci
convent
sensit
specif
cpi
sensit
specif
diagnosi
howev
although
cpi
shown
improv
diagnost
accuraci
compar
convent
clinic
assess
use
success
monitor
modifi
therapi
prospect
multicentr
cohort
studi
ventil
patient
suspect
vap
use
serial
measur
cpi
monitor
clinic
cours
vap
success
identifi
patient
good
prognosi
day
studi
investig
patient
pulmonari
infiltr
suspect
vap
cpi
score
low
likelihood
pneumonia
patient
random
receiv
standard
therapi
ciprofloxacin
monotherapi
discontinu
day
cpi
remain
compar
patient
standard
therapi
ciprofloxacin
monotherapi
significantli
lower
antimicrobi
cost
antimicrobi
resist
superinfect
differ
length
stay
mortal
author
conclud
cpi
could
use
identifi
patient
would
benefit
short
cours
antibiot
recommend
although
clinic
diagnosi
hap
difficult
follow
criteria
identifi
patient
pneumonia
consid
differenti
diagnosi
purul
tracheal
secret
new
andor
persist
infiltr
cxr
otherwis
unexplain
increas
oxygen
requir
core
temperatur
blood
leucocytosi
leucopenia
recommend
cpi
may
use
select
patient
shortcours
therapi
monitor
respons
treatment
recommend
grade
c
littl
avail
evid
assess
valu
imag
investig
diagnosi
hap
vap
one
systemat
review
review
diagnost
studi
focus
vap
broader
topic
hap
public
diagnost
imag
vaphap
mainli
limit
use
cxr
littl
inform
techniqu
comput
axial
tomographi
ct
magnet
reson
mr
positron
emiss
tomographi
pet
newer
techniqu
use
initi
investig
ct
use
addit
diagnost
tool
exclud
patholog
patient
complex
cxr
role
mr
pet
diagnosi
hapvap
assess
diagnost
valu
cxr
usual
greater
hap
vap
problem
perform
mobil
radiograph
investig
ventil
patient
move
cardiothorac
comorbid
often
present
patient
ventil
patient
may
abnorm
cxr
secondari
patholog
must
distinguish
infect
eg
acut
lung
injuri
left
ventricular
failur
aspir
alveolar
haemorrhag
radiolog
investig
patient
vap
often
influenc
outcom
use
patient
nonventil
hap
may
provid
inform
differenti
diagnosi
complic
exclus
patholog
therefor
although
presenc
alveolar
infiltr
cxr
rais
possibl
hap
well
differenti
diagnos
key
imag
investig
establish
diagnosi
hap
though
normal
cxr
exclud
hap
recommend
diagnosi
hap
consid
good
qualiti
cxr
obtain
compar
previou
cxr
avail
recommend
grade
ct
scan
may
assist
differenti
diagnosi
hap
may
guid
manag
patient
respond
treatment
complex
cxr
recommend
grade
gpp
literatur
microbiolog
hapvap
extens
consist
mainli
observ
studi
base
surveil
epidemiolog
wide
rang
bacteria
associ
hap
vap
tabl
common
organ
isol
respiratori
specimen
patient
known
suspect
hap
p
aeruginosa
aureu
enterobacteriacea
especi
klebsiella
e
coli
enterobact
spp
polymicrobi
cultur
common
vap
occur
case
studi
anaerob
fungi
uncommon
mani
microbi
surveil
studi
use
quantit
microbiolog
specimen
collect
invas
techniqu
agreement
criteria
distinguish
colon
infect
mani
studi
simpli
report
isol
without
assess
signific
cultur
result
interpret
caution
longer
patient
hospit
wider
spectrum
like
pathogen
like
multipl
drug
resist
earlyonset
hap
vap
often
caus
typic
antimicrobialsuscept
commun
organ
streptococcu
pneumonia
haemophilu
influenza
lateonset
hap
vap
commonli
caus
p
aeruginosa
antimicrobialresist
opportunist
gramneg
bacteria
mrsa
howev
studi
found
increas
frequenc
earlyonset
hap
caus
nosocomi
pathogen
probabl
result
recent
prior
hospit
andor
antimicrobi
therapi
refer
hcap
see
section
resist
rate
nosocomi
pathogen
kind
increas
particularli
icu
trend
reflect
increas
resist
respiratori
isol
hap
especi
lateonset
vap
howev
rel
frequenc
organ
involv
vari
locat
date
studi
tabl
although
direct
evidencebas
recommend
made
microbiolog
surveil
data
recommend
assess
causal
pathogen
hap
therapi
guid
publish
nation
intern
literatur
local
surveil
data
result
microbiolog
investig
individu
patient
recommend
grade
gpp
organ
isol
respiratori
specimen
individu
patient
regard
pathogen
necessarili
requir
therapi
interpret
treat
light
full
clinic
pictur
necessari
consult
microbiologist
clinician
recommend
grade
gpp
probabl
univers
accept
pathogen
pneumococci
isol
respiratori
specimen
patient
suspect
hap
treat
recommend
grade
gpp
blood
cultur
isol
contamin
gener
regard
signific
pathogen
requir
treatment
howev
prospect
observ
studi
icu
patient
evid
vap
found
poor
correl
organ
isol
blood
cultur
bal
studi
bacteraemia
associ
increas
complic
length
stay
sever
ill
mortal
author
conclud
organ
isol
blood
necessarili
caus
vap
recommend
consid
diagnosi
hap
signific
blood
isol
review
light
patient
clinic
condit
consult
clinician
microbiologist
recommend
grade
gpp
microbiolog
investig
hap
includ
microscopi
qualit
quantit
cultur
respiratori
secret
sputum
poor
diagnost
specimen
may
come
infect
area
contamin
upper
respiratori
flora
collect
obtain
specimen
accur
reflect
bacteri
burden
deep
within
lung
method
develop
collect
lower
respiratori
sampl
protect
oropharyng
contamin
includ
bronchoscopydirect
method
nonbronchoscop
blind
techniqu
commonli
analys
direct
method
bronchoscopydirect
bal
bronchoscopydirect
protect
specimen
brush
psb
sampl
common
nondirect
method
blind
bal
et
aspir
mani
studi
compar
qualit
quantit
microbiolog
result
lower
respiratori
specimen
obtain
differ
sampl
method
studi
vap
sever
highqual
review
diagnost
valu
quantit
cultur
respiratori
secret
collect
bronchoscopydirect
psb
bal
systemat
review
studi
direct
psb
similar
review
direct
bal
analys
paper
metaanalysi
assess
psb
bal
studi
conclud
signific
differ
diagnost
accuraci
quantit
microbiolog
specimen
collect
bronchoscopydirect
psb
bal
studi
blind
bronchial
sampl
blind
minib
blind
sampl
psb
diagnosi
vap
found
diagnost
accuraci
blind
sampl
similar
bronchoscopydirect
method
side
effect
also
similar
two
recent
cohort
studi
shown
signific
differ
use
bronchoscop
psb
blind
psb
bronchoscop
bal
differ
blind
direct
protect
telescop
cathet
bronchoscop
bal
evid
conclud
differ
result
obtain
psb
bal
advantag
use
bronchoscop
direct
method
compar
blind
sampl
ea
attract
specimen
microbiolog
sampl
sinc
simpl
safe
obtain
unskil
staff
systemat
review
report
publish
accuraci
ea
cultur
diagnosi
vap
conclud
sensit
specif
quantit
ea
cultur
vari
wide
sensit
specif
qualit
ea
cultur
high
sensit
moder
posit
predict
valu
high
neg
predict
valu
author
conclud
ea
cultur
unreli
diagnosi
vap
use
ea
sampl
analys
three
morerec
paper
studi
ventil
trauma
patient
strong
clinic
radiolog
evid
vap
assess
made
sampl
respiratori
secret
ea
direct
psb
blind
protect
brush
via
et
tube
bronchoscopydirect
bal
valu
quantifi
percentag
infect
cell
specimen
gram
stain
also
analys
moder
agreement
kappa
k
analysi
quantit
cultur
ea
bal
sensit
specif
quantif
infect
cell
ea
sampl
use
quantit
cultur
bal
standard
respect
anoth
cohort
studi
identifi
patient
vap
base
clinic
evid
cultur
result
bal
evalu
signific
quantit
cultur
diagnost
threshold
cfuml
ea
cfuml
bal
studi
report
sensit
specif
posit
predict
valu
neg
predict
valu
correct
classif
pneumonia
pneumonia
ea
bal
respect
thu
ea
perform
less
well
bal
similar
sensit
lower
specif
fewer
correct
classif
anoth
studi
evalu
diagnost
valu
gram
stain
identif
intracellular
organ
ea
sampl
ventil
patient
use
two
cutoff
point
infect
cell
usual
tradeoff
sensit
specif
comparison
quantit
cultur
ea
sampl
presenc
intracellular
organ
cell
sensit
specif
posit
predict
valu
neg
predict
valu
outcom
consid
patient
eventu
treat
vap
attend
physician
ea
intracellular
organ
count
quantit
cultur
cfuml
least
one
specimen
howev
patient
treat
pneumonia
intracellular
count
studi
support
conclus
ea
specimen
high
sensit
identifi
bacteria
respiratori
specimen
low
specif
demonstr
improv
patient
manag
thu
evid
support
use
ea
specimen
diagnosi
vaphap
either
cultur
microscopi
quantit
qualit
recommend
ea
cultur
use
diagnosi
vap
recommend
grade
recommend
evid
one
invas
sampl
method
better
recommend
least
expens
least
invas
rapid
sampl
techniqu
requir
minim
expertis
use
establish
microbiolog
diagnosi
hap
eg
nonbronchoscopydirect
blind
bal
recommend
grade
gpp
role
quantit
microbiolog
diagnosi
hapvap
although
larg
amount
data
assess
diagnost
accuraci
quantit
microbiolog
publish
littl
high
qualiti
central
problem
good
refer
standard
diagnosi
hap
microbiolog
result
usual
compar
one
combin
clinic
microbiolog
eg
tissu
histolog
diagnos
describ
none
refer
standard
reliabl
wide
varieti
invas
sampl
techniqu
quantit
microbiolog
criteria
cutoff
point
use
ea
reliabl
microbiolog
analysi
wherea
describ
sampl
method
give
similar
result
systemat
review
seri
use
quantit
microbiolog
diagnosi
hapvap
review
psb
bal
wherea
metaanalysi
review
use
psb
specimen
also
three
consensu
review
four
good
qualiti
gener
review
topic
one
systemat
review
sensit
quantit
bal
cultur
rang
mean
specif
rang
mean
thu
falseneg
result
occur
case
fals
posit
review
similar
find
howev
evidencebas
guidelin
conclud
neg
lower
respiratori
tract
cultur
patient
recent
chang
antibiot
therapi
indic
stop
antibiot
studydefin
evid
level
moder
good
repeat
bal
specimen
analys
qualit
quantit
although
lavag
specimen
usual
taken
one
lung
evid
bilater
lavag
may
accur
thu
quantit
cultur
respiratori
specimen
improv
diagnosi
hapvap
method
wide
rang
accuraci
high
likelihood
falseneg
falseposit
result
misdiagnos
hapvap
case
although
may
provid
indic
causal
pathogen
recommend
quantit
cultur
respiratori
specimen
psb
bal
reli
diagnosi
hapvap
recommend
grade
quantif
intracellular
organ
diagnosi
hap
intracellular
organ
polymorph
respiratori
specimen
visual
microscop
varieti
stain
method
quantif
infect
cell
propos
rapid
method
diagnosi
pneumonia
three
recent
cohort
studi
compar
techniqu
studi
compar
quantit
cultur
minib
specimen
percentag
intracellular
organ
specimen
found
cutoff
infect
cell
gave
sensit
specif
second
trial
determin
sensit
specif
infect
cell
bronchoscop
bal
specimen
cutoff
respect
studi
therapeut
plan
consid
correct
case
use
clinic
judgment
alon
guid
microscopi
result
quantit
cultur
bal
specimen
describ
diagnost
sensit
specif
posit
predict
valu
neg
predict
valu
correct
classif
pneumonia
pneumonia
respect
use
quantif
intracellular
organ
specimen
cultur
cutoff
point
cfuml
valu
respect
thu
comparison
quantit
cultur
detect
intracellular
organ
bal
specimen
rapid
specif
test
high
posit
predict
valu
recommend
quantif
intracellular
organ
bal
specimen
rapid
specif
test
use
guid
initi
therapi
recommend
grade
treatment
use
system
antibiot
alon
conjunct
topic
appli
nonabsorb
antibiot
part
sdd
regimen
investig
prevent
hap
particularli
vap
two
recent
systemat
review
recent
metaanalysi
cochran
review
consid
benefit
sdd
prevent
hap
review
demonstr
signific
reduct
hap
respiratori
infect
one
systemat
review
also
demonstr
signific
reduct
overal
mortal
sdd
wherea
anoth
show
reduct
mortal
critic
ill
surgic
patient
final
systemat
review
found
signific
mortal
reduct
howev
cochran
review
report
combin
topic
system
prophylact
antibiot
reduc
respiratori
tract
infect
overal
mortal
adult
patient
receiv
intens
care
treatment
base
use
topic
prophylaxi
alon
reduc
respiratori
infect
mortal
recent
metaanalysi
examin
relationship
methodolog
trial
qualiti
effect
sdd
found
better
qualiti
research
paper
defin
score
method
demonstr
less
benefit
term
pneumonia
reduct
although
small
signific
reduct
mortal
found
highqual
studi
five
rct
includ
metaanalys
also
assess
consist
report
benefit
sdd
quantif
potenti
benefici
impact
use
sdd
undertaken
metaanalysi
rct
show
number
patient
need
treatment
nnt
prevent
one
case
vap
prevent
one
death
cochran
review
report
averag
patient
need
treat
sdd
prevent
one
respiratori
tract
infect
patient
prevent
one
death
result
rct
assess
worker
consist
nnt
prevent
one
death
patient
thu
evid
benefit
sdd
consist
demonstr
across
patient
group
reduct
morbid
mortal
associ
vap
also
good
evid
reduct
respiratori
tract
infect
affect
mortal
evid
critic
ill
patient
vap
less
clear
translat
form
hap
insuffici
evid
assess
particular
patient
subgroup
benefit
significantli
other
recommend
anticip
mechan
ventil
h
sdd
consid
icu
patient
order
prevent
develop
vap
recommend
grade
two
recent
metaanalys
address
best
method
sdd
studi
found
greatest
reduct
respiratori
infect
observ
topic
system
compon
treatment
administ
recent
rct
perform
use
topic
sdd
alon
demonstr
signific
reduct
vap
patient
receiv
modifi
sdd
topic
regimen
polymyxin
tobramycin
amphotericin
differ
mortal
two
group
found
wide
rang
choic
drug
dose
employ
sdd
avail
evid
best
regimen
regard
durat
administr
trial
consist
use
sdd
throughout
icu
stay
system
element
given
day
subject
modif
treatment
sepsi
research
sdd
need
determin
best
regimen
identifi
best
select
agent
unit
particularli
resist
organ
eg
mrsa
multidrugresist
acinetobact
spp
extendedspectrum
blactamaseproduc
organ
recommend
sdd
regimen
includ
topic
parenter
agent
activ
gramneg
bacilli
choic
treatment
depend
local
pathogen
antimicrobi
suscept
profil
recommend
grade
metaanalysi
report
practic
sdd
led
trend
toward
colon
patient
gramposit
organ
pneumonia
due
resist
gramposit
organ
effect
statist
signific
cochran
review
found
evid
gener
emerg
resist
isol
report
rct
describ
chang
compar
sdd
convent
manag
patient
gramposit
resist
though
reduct
gramneg
resist
although
anoth
rct
found
increas
gramposit
organ
includ
mrsa
group
treat
sdd
felt
relat
possibl
crossinfect
problem
thu
absenc
evid
use
sdd
result
emerg
gener
spread
resist
isol
report
problem
aris
unit
deploy
sdd
describ
view
emerg
resist
pattern
gramposit
gramneg
bacteria
current
encount
uk
hospit
research
requir
assess
longterm
effect
sdd
antimicrobi
resist
also
evalu
effect
sdd
develop
c
difficil
infect
recommend
use
sdd
withheld
concern
develop
antibiot
resist
recommend
grade
recommend
sdd
requir
support
good
infect
control
plan
prospect
suscept
surveil
order
problem
identifi
earli
address
recommend
grade
gpp
costeffect
sdd
sdd
carri
cost
respect
pharmaci
opportun
cost
well
fund
requir
support
concomit
antimicrobi
resist
surveil
activ
rct
spain
franc
holland
structur
assess
clinic
outcom
costeffect
relat
cost
per
survivor
resourc
cost
vari
countri
countri
studi
assum
appli
nation
either
term
quantum
direct
howev
four
rct
assess
cost
per
survivor
demonstr
sdd
costeffect
procedur
recommend
although
initi
expenditur
implement
sdd
may
higher
standard
manag
use
sdd
costeffect
term
individu
cost
per
survivor
recommend
grade
b
cost
vari
countri
recommend
estim
local
cost
made
sdd
protocol
unit
recommend
grade
gpp
evid
three
rct
use
system
prophylaxi
alon
benefici
reduc
risk
vap
ventil
patient
neurolog
trauma
burn
assess
potenti
resist
emerg
assess
studi
first
full
treatment
dose
use
wherea
second
although
trend
reduct
mortal
shown
studi
underpow
observ
signific
differ
final
trial
poorest
qualiti
enrol
least
number
patient
observ
blind
treatment
alloc
magnitud
treatment
effect
system
antibiot
prophylaxi
alon
less
sdd
sdd
thu
prefer
good
studi
avail
relationship
modern
surgic
antibiot
prophylaxi
practic
develop
outcom
hap
recommend
system
antibiot
prophylaxi
alon
use
prevent
hap
part
sdd
regimen
recommend
grade
b
larg
bodi
evid
use
antimicrobi
manag
hap
rct
past
three
decad
howev
sever
earlier
studi
evalu
antibiot
longer
regard
appropri
empir
therapi
patient
hap
particularli
lateonset
infect
owe
dramat
chang
natur
suscept
pattern
pathogen
current
recogn
uk
hospit
moreov
wellconduct
studi
undertaken
pharmacoeconom
health
econom
evalu
mani
limit
qualiti
avail
evid
assist
approach
antimicrobi
select
hap
studi
compar
two
therapeut
option
studi
suffici
power
demonstr
superior
one
regimen
anoth
limit
primari
microbiolog
evalu
invari
relat
patient
whose
pathogen
suscept
trial
antibiot
six
studi
recruit
patient
treatment
compar
arm
five
studi
random
doubleblind
studi
sever
studi
patient
enrol
likelihood
type
ii
error
high
final
none
studi
address
patient
demographi
risk
factor
assess
empir
definit
treatment
relat
sever
ill
durat
hospit
studi
differenti
gramposit
gramneg
pathogen
alon
studi
look
mix
gramposit
neg
pathogen
sever
studi
enrol
patient
either
ventil
nonventil
therapi
activ
pathogen
differ
group
term
assess
outcom
whether
clinic
microbiolog
reason
possibl
identifi
optim
antibiot
regimen
howev
although
pathogen
suscept
pattern
associ
lateonset
hap
highli
variabl
found
earlyonset
infect
number
remark
consist
centr
centr
see
section
recommend
choic
empir
antibiot
therapi
patient
hap
individu
unit
base
knowledg
natur
suscept
pattern
pathogen
preval
unit
also
take
account
variabl
durat
hospit
stay
ie
earlyor
lateonset
infect
recent
administr
antibiot
therapi
comorbid
similarli
definit
therapi
determin
cultur
suscept
test
result
recommend
grade
patient
earlyonset
infect
fewer
day
follow
admiss
hospit
previous
receiv
antibiot
absenc
risk
factor
use
coamoxiclav
cefuroxim
would
appropri
recommend
grade
gpp
patient
earlyonset
infect
fewer
day
follow
admiss
hospit
recent
receiv
antibiot
andor
risk
factor
thirdgener
cephalosporin
cefotaxim
ceftriaxon
fluoroquinolon
piperacillintazobactam
would
appropri
recommend
grade
gpp
role
invas
sampl
quantit
microbiolog
respiratori
secret
direct
antimicrobi
therapi
hapvap
describ
invas
sampl
quantit
microbiolog
respiratori
secret
low
specif
sensit
diagnosi
hapvap
use
techniqu
direct
modifi
antibiot
therapi
suspect
vap
therefor
controversi
sever
studi
investig
whether
treatment
base
invas
quantit
microbiolog
improv
patient
outcom
prospect
nonrandom
cohort
studi
patient
without
diagnost
bronchoscopi
quantit
analysi
bronchoscopydirect
psb
bal
specimen
found
bronchoscopi
group
durat
ventil
icu
stay
similar
mortal
lower
versu
p
studi
also
report
bronchoscopi
patient
receiv
fewer
antibiot
like
discontinu
antibiot
find
support
retrospect
cohort
studi
demonstr
manag
base
quantit
bronchoscopi
rather
cpi
result
reduc
antibiot
prescrib
howev
former
work
although
physician
confid
diagnosi
vap
diagnost
bronchoscopi
antibiot
discontinu
patient
growth
psb
bal
sampl
four
rigor
random
prospect
studi
icu
patient
suspect
vap
perform
measur
outcom
manag
base
either
clinic
assess
microscopi
andor
quantit
nonquantit
cultur
ea
clinic
manag
ii
microscopi
andor
quantit
cultur
psb
bal
specimen
invas
manag
larg
multicentr
studi
involv
patient
found
invas
manag
significantli
associ
fewer
death
day
earlier
improv
organ
dysfunct
less
antibiot
use
differ
length
icu
stay
hospit
stay
ventil
smaller
studi
involv
patient
respect
differ
length
stay
icu
length
ventil
mortal
found
addit
last
studi
detect
differ
chang
antibiot
therapi
wide
assum
treatment
outcom
hapvap
affect
suscept
infect
organ
howev
limit
evid
confirm
patient
vap
may
difficulti
make
certain
diagnosi
pneumonia
identifi
caus
pathogen
addit
microbiolog
result
may
come
late
influenc
outcom
andor
broadspectrum
empir
therapi
often
use
microbiolog
diagnosi
confirm
nevertheless
organ
bal
specimen
resist
empir
therapi
independ
associ
mortal
infect
usual
multipli
resist
p
aeruginosa
acinetobact
spp
associ
higher
mortal
pathogen
recent
retrospect
cohort
studi
vap
associ
acinetobact
baumannii
significantli
associ
attribut
mortal
increas
length
icu
stay
whether
isol
carbapenemresist
anoth
recent
studi
patient
treat
time
appropri
antimicrobi
therapi
show
differ
outcom
patient
vap
associ
mrsa
methicillinsuscept
aureu
data
demonstr
influenc
vap
delay
start
appropri
therapi
initi
inappropri
antibiot
therapi
increas
mortal
rate
length
time
patient
spend
mechan
ventil
hospit
howev
mani
studi
poor
design
differ
statist
differ
delay
institut
therapi
withhold
therapi
await
cultur
result
associ
increas
mortal
rate
two
studi
one
studi
investig
nonintub
hap
patient
studi
involv
ventil
patient
radiolog
clinic
evid
vap
undertook
quantit
cultur
bronchoscopydirect
bal
specimen
within
h
clinic
radiolog
diagnosi
posit
bal
specimen
defin
contain
cfuml
bacteria
patient
strong
clinic
suspicion
vap
high
mortal
rate
regardless
whether
bal
cultur
confirm
clinic
diagnosi
balposit
patient
receiv
antibiot
therapi
appropri
cultur
prior
bronchoscopi
mortal
compar
p
therapi
inappropri
treatment
given
patient
chang
inadequ
adequ
therapi
base
bal
result
mortal
compar
continu
receiv
inadequ
therapi
thu
even
quantit
microbiolog
bronchoscopydirect
bal
specimen
correctli
identifi
appropri
antimicrobi
therapi
inform
becom
avail
late
influenc
surviv
recommend
inadequ
evid
support
use
invas
quantit
microbiolog
diagnosi
initi
therapi
improv
outcom
vap
individu
patient
recommend
grade
c
recommend
initi
appropri
antibiot
therapi
institut
soon
vap
suspect
base
local
microbiolog
surveil
data
recommend
grade
c
recommend
initi
therapi
delay
await
microbiolog
result
recommend
grade
c
durat
antimicrobi
treatment
manag
hap
blind
multicentr
rct
patient
treat
antibiot
either
day
bacteriolog
confirm
lateonset
vap
receiv
shorter
durat
treatment
differ
convent
treat
counterpart
term
mortal
icu
stay
major
clinic
outcom
resolut
fever
white
blood
cell
count
arteri
oxygen
emerg
multiresist
pathogen
lower
receiv
day
cours
overal
use
antibiot
also
lower
recommend
patient
respond
therapi
routin
durat
empir
therapi
longer
day
recommend
grade
c
recommend
order
reduc
mortal
morbid
patient
vap
treatment
appropri
antibiot
start
soon
possibl
recommend
grade
c
definit
treatment
caus
organ
p
aeruginosa
infect
caus
p
aeruginosa
associ
significantli
higher
incid
treatment
failur
caus
organ
subgroup
analysi
studi
imipenem
one
antibiot
evalu
shown
statist
increas
incid
treatment
failur
compar
ceftazidim
p
piperacillin
tazobactam
p
larg
doubleblind
studi
ciprofloxacin
compar
imipenem
show
statist
signific
differ
two
drug
term
erad
p
aeruginosa
patient
hap
although
overal
accord
univari
analysi
ci
differ
p
multipl
logist
regress
analysi
ci
p
ciprofloxacin
effect
term
clinic
bacteriolog
cure
rate
patient
infect
caus
gramneg
bacilli
p
aeruginosa
compar
combin
ceftazidim
tobramycin
administr
meropenem
also
demonstr
associ
higher
incid
treatment
failur
patient
hap
caus
p
aeruginosa
although
overal
latter
produc
higher
clinic
microbiolog
cure
rate
p
respect
recommend
proven
optim
antibiot
regimen
patient
hap
suspect
proven
caus
p
aeruginosa
treatment
option
includ
ceftazidim
ciprofloxacin
meropenem
piperacillintazobactam
recommend
gpp
efficaci
two
novel
antibiot
evalu
therapi
patient
infect
caus
specif
gramposit
bacteria
particular
mrsa
quinapristin
dalfopristin
linezolid
versu
vancomycin
linezolid
versu
teicoplanin
howev
unlik
studi
suffici
power
demonstr
superior
two
retrospect
analys
combin
data
two
doubleblind
studi
involv
linezolid
first
conclud
linezolid
associ
higher
surviv
p
clinic
cure
p
rate
vancomycin
patient
hap
caus
mrsa
second
analysi
vap
patient
show
increas
surviv
p
bacteri
erad
p
clinic
cure
p
rate
howev
although
patient
evalu
two
trial
actual
document
infect
caus
mrsa
recommend
basi
publish
studi
difficulti
interpret
result
subgroup
analysi
firm
conclus
reach
use
linezolid
glycopeptid
optim
treatment
patient
hap
vap
caus
mrsa
recommend
grade
gpp
role
pharmacokinet
pk
pharmacodynam
pd
antibiot
featur
guid
treatment
select
hap
small
bodi
evid
avail
three
cohort
studi
role
pkpd
assess
manag
pneumonia
howev
studi
retrospect
theoret
model
antimicrobi
manag
rather
prospect
rct
therefor
reason
appropri
extrapol
find
small
number
studi
treatment
hap
whole
prospect
rct
progress
explor
valu
pk
pd
guid
treatment
choic
hap
recommend
current
state
knowledg
pkpd
model
use
guid
treatment
select
hap
recommend
grade
choic
monotherapi
combin
therapi
treatment
hap
systemat
review
directli
relev
question
sixteen
rct
enrol
patient
hap
compar
patient
receiv
monotherapi
carbapenem
cephalosporin
ureidopenicillin
receiv
combin
therapi
cephalosporin
carbapenem
penicillin
azlocillin
carbenicillin
coamoxiclav
ticarcillin
aminoglycosid
two
compar
blactam
without
aminoglycosid
studi
evid
clinic
bacteriolog
respons
rate
improv
combin
therapi
cephalosporin
carbapenem
penicillin
aminoglycosid
also
evid
use
combin
aminoglycosid
one
class
blactam
cephalosporin
carbapenem
penicillin
effect
other
term
clinic
bacteriolog
respons
rate
howev
studi
suffici
power
enabl
superior
detect
systemat
review
consid
evid
monotherapi
versu
combin
therapi
treatment
nonneutropen
patient
seriou
infect
includ
pneumonia
found
equival
howev
increas
incid
toxic
observ
patient
receiv
combin
therapi
includ
aminoglycosid
recommend
wherev
possibl
antimicrobi
monotherapi
use
manag
bacteri
hap
recommend
grade
airway
administr
antimicrobi
manag
hap
pk
studi
demonstr
high
concentr
aminoglycosid
achiev
bronchial
secret
drug
administ
either
instil
nebul
via
et
tube
howev
ceftazidim
imipenem
achiev
significantli
higher
concentr
administ
instil
nebul
one
rct
evalu
efficaci
antibiot
tobramycin
instil
via
et
tube
patient
vap
caus
gramneg
bacteria
also
receiv
parenter
therapi
compar
placebo
bacteriolog
cure
rate
significantli
higher
studi
group
howev
signific
differ
group
term
clinic
cure
rate
cultureposit
popul
emerg
resist
occur
frequent
studi
group
compar
control
group
final
statist
signific
differ
group
term
incid
advers
reaction
except
higher
frequenc
supraventricular
tachycardia
among
patient
studi
group
small
sampl
size
larg
number
patient
could
evalu
major
defici
studi
second
rct
tobramycin
placebo
nebul
via
et
tube
patient
vap
patient
also
treat
parenter
antibiot
statist
signific
differ
group
term
time
extub
toler
studi
suffer
small
sampl
size
systemat
review
patient
cf
demonstr
aerosol
antipseudomon
antibiot
associ
statist
signific
reduct
incid
acut
exacerb
applic
find
patient
vap
uncertain
worthi
studi
limit
exist
publish
trial
togeth
absenc
robust
evid
preclud
firm
conclus
regard
efficaci
topic
antibiot
adjunct
therapi
patient
vap
recommend
insuffici
evid
administr
topic
antibiot
adjunct
parenter
therapi
benefici
patient
vap
routin
implement
intervent
warrant
recommend
grade
antibiot
given
et
rout
instil
et
tube
oppos
nebul
prefer
rout
administr
recommend
grade
gpp
switch
intraven
oral
antimicrobi
therapi
manag
hap
three
rct
assess
efficaci
switch
intraven
oral
therapi
treatment
hap
studi
design
examin
compar
antibiot
rather
specif
address
benefit
switch
intraven
oral
formul
low
number
patient
power
show
differ
treatment
comparison
studi
report
includ
definit
inform
criteria
use
determin
switch
patient
intraven
oral
formul
henc
avail
evid
uninterrupt
determin
switch
intraven
oral
therapi
hap
recommend
made
target
research
requir
topic
recommend
establish
evid
upon
base
convers
intraven
oral
treatment
manag
hap
decis
must
taken
case
case
basi
accord
therapeut
clinic
respons
treatment
recommend
grade
therapeut
modal
antimicrobi
manag
hap
one
larg
good
qualiti
rct
conduct
hospit
patient
sepsi
organ
failur
compar
activ
protein
c
placebo
studi
includ
centr
recruit
patient
receiv
antibiot
addit
trial
therapi
trial
stop
earli
follow
interim
analysi
due
mortal
benefit
activ
protein
c
treat
group
final
mortal
result
base
patient
pneumonia
demonstr
reduct
rel
risk
death
p
breakdown
hap
cap
provid
therefor
trial
consid
definit
proof
improv
hap
outcom
activ
protein
c
nevertheless
consid
highli
like
substanti
proport
pneumonia
larg
trial
hospitalacquir
studi
activ
protein
c
patient
diagnos
hap
requir
confirm
gener
find
recommend
patient
sepsi
organ
failur
hap
consid
treatment
activ
protein
c
accord
manufactur
guidanc
use
recommend
grade
b
systemat
review
four
rct
investig
role
drug
promot
increas
white
blood
cell
product
immunocompet
patient
hap
one
studi
assess
safeti
two
other
use
draw
conclus
patient
number
small
remain
rct
assess
efficaci
patient
acquir
np
though
breakdown
provid
distribut
patient
addit
antibiot
therapi
random
treatment
gcsf
placebo
studi
demonstr
improv
mortal
pneumonia
outcom
term
treatment
gcsf
placebo
therefor
evid
show
gcsf
benefici
treatment
hap
recommend
patient
sepsi
hap
treat
gcsf
recommend
grade
chest
physiotherapi
commonli
use
patient
hap
rct
assess
effect
physiotherapi
combin
positivepressur
breath
pneumonia
outcom
evalu
patient
clinic
diagnos
pneumonia
signific
differ
outcom
durat
fever
length
stay
mortal
observ
breakdown
acquir
np
provid
assess
power
studi
detect
differ
undertaken
therefor
evid
support
improv
hap
outcom
chest
physiotherapi
chest
physiotherapi
recommend
direct
manag
patient
hap
due
lack
evid
demonstr
improv
outcom
recommend
grade
b
chest
physiotherapi
may
valu
patient
suffer
risk
hap
might
appropri
consid
therapeut
option
broader
context
recommend
grade
gpp
evid
assess
effect
steroid
hap
limit
two
cohort
studi
identifi
one
pilot
studi
base
outbreak
branhamella
catarrhali
neither
studi
directli
relev
issu
hap
assert
recommend
made
recommend
absenc
clear
evid
benefit
routin
use
steroid
manag
case
hap
promot
recommend
grade
use
clinic
protocol
treat
hap
literatur
investig
use
protocol
pneumonia
either
focus
cap
look
prevent
diagnosi
hap
rather
treatment
literatur
relat
impact
guidelinesprotocol
pneumonia
extens
evalu
review
review
conclud
clinic
guidelinesprotocol
outlin
number
key
intervent
improv
deliveri
antibiot
procur
microbiolog
test
may
improv
clinic
effect
howev
littl
inform
exist
around
singl
intervent
work
cost
would
seem
plausibl
hypothes
basi
studi
one
may
abl
draw
similar
manag
hap
vap
data
specif
area
limit
rct
employ
clinic
protocol
util
modifi
cpi
select
patient
low
risk
hap
would
deem
suitabl
earli
discontinu
day
empir
therapi
hap
compar
standard
durat
choic
therapi
clinician
discret
ciprofloxacin
monotherapi
result
confirm
earli
discontinu
empir
therapi
associ
increas
mortal
shorter
durat
stay
cost
associ
lower
rate
antibiot
resist
superinfect
conclud
protocol
empir
therapi
guid
clinic
decis
durat
therapi
base
cpi
could
improv
econom
microbiolog
outcom
without
compromis
clinic
effect
howev
studi
blind
primarili
one
centr
consist
mostli
elderli
men
chronic
underli
diseas
bias
fact
clinician
began
minim
antibiot
polypharmaci
durat
therapi
compar
standard
treatment
arm
studi
progress
studi
therefor
requir
valid
differ
popul
sever
form
hap
uncontrol
studi
examin
impact
vap
guidelin
primari
outcom
appropri
initi
empir
antibiot
therapi
judg
subsequ
posit
cultur
secondari
studi
outcom
includ
durat
therapi
mortal
secondari
episod
vap
length
hospit
stay
studi
imbalanc
signific
differ
baselin
preval
comorbid
copd
congest
cardiac
failur
serum
albumin
also
differ
treatment
eg
dialysi
sucralf
follow
implement
vap
guidelin
studi
demonstr
improv
appropri
prescrib
p
reduct
durat
antibiot
therapi
day
p
subsequ
episod
vap
p
studi
examin
costeffect
impact
microbiolog
outcom
poor
design
studi
noncompar
patient
popul
indic
data
insuffici
robust
definit
support
implement
vap
guidelin
improv
outcom
defin
rct
patient
vap
medic
icu
explor
relationship
clinic
protocol
respect
costeffect
activ
antibiot
discontinu
polici
alter
patient
outcom
hospit
stay
result
day
reduct
antibiot
use
associ
cost
save
nonblind
rct
investig
protocol
empir
therapi
patient
low
risk
hap
found
protocol
reduc
durat
unnecessari
antibiot
therapi
length
hospit
stay
cost
also
reduc
incid
superinfect
resist
welldesign
prospect
intervent
studi
requir
assess
impact
specif
hapvap
guidelin
protocol
heterogen
popul
sever
hapvap
recommend
clinic
guidelin
protocol
empir
therapi
hapvap
introduc
certain
clinic
set
abl
improv
econom
microbiolog
outcom
without
compromis
efficaci
recommend
grade
c
prepar
guidelin
first
step
without
wide
dissemin
recommend
implement
audit
work
group
vain
littl
evid
avail
support
guidelin
introduct
need
research
area
sit
alongsid
gap
knowledg
highlight
paper
research
feedback
come
new
knowledg
import
content
document
kept
review
ensur
reflect
best
avail
contemporari
evid
sinc
complet
guidelin
sever
refer
updat
internet
site
current
list
given
public
bsac
publish
guidelin
manag
mrsa
sepsi
includ
comment
upon
hospitalacquir
lower
respiratori
tract
infect
fund
wyeth
pharmaceut
ltd
provid
unrestrict
educ
grant
use
secretariat
support
throughout
project
g
receiv
fund
speak
symposium
organ
behalf
wyeth
pharmaceut
ltd
r
receiv
person
remuner
speak
educ
meet
organ
wyeth
r
g
receiv
speaker
honoraria
astrazeneca
wyeth
n
present
member
number
uk
european
pharmaceut
advisori
board
tigecyclin
wyeth
ceftobiprol
janssencilag
daptomycin
novarti
linezolid
pfizer
optim
receiv
honoraria
speak
meet
organ
pfizer
wyeth
novarti
w
receiv
honoraria
consult
work
financi
support
attend
meet
research
fund
astrazeneca
bayer
genzym
nabriva
pfizer
vicuron
wyeth
g
receiv
fund
speak
symposia
organ
behalf
wyeth
e
b
receiv
fee
speak
symposium
sponsor
novarti
member
advisori
panel
chiron
novarti
janssencilag
also
receiv
sponsorship
chiron
attend
confer
j
k
g
f
p
j
c
c
f
none
declar
work
parti
report
put
public
consult
decemb
februari
amend
light
comment
receiv
prior
submiss
jac
nation
consult
exercis
involv
major
stakehold
interest
parti
individu
replac
jac
standard
peer
review
process
submiss
final
review
decisionmak
process
undertaken
editorinchief
consult
anoth
member
editori
board
neither
member
work
parti
